Prohibits the Rhode Island medical assistance program and managed care organizations that it contracts with from requiring prior authorization or step therapy protocol for a prescription of a nonpreferred anticonvulsant or antipsychotic.
Summary
H5320 would amend Rhode Island’s medical assistance prescription drug laws to bar the Rhode Island medical assistance program, and any managed care organization contracting with it, from requiring prior authorization or step therapy for nonpreferred medications classified as anticonvulsants or antipsychotics. The bill also defines “step therapy protocol” and makes clear that the prohibition does not eliminate clinical prior authorization edits or prevent denial of coverage for drugs removed from the market by the FDA for safety reasons.
The measure applies to Medicaid-related policies, contracts, plans, and certificates issued, renewed, or continued on or after January 1, 2026. It would require the executive office of health and human services to amend current and future managed care contracts to ensure compliance, and it allows the state to seek any federal approval needed before implementation.
Impact
The bill would directly change how Rhode Island Medicaid and Medicaid managed care plans manage access to certain mental health and seizure medications by limiting utilization management tools for nonpreferred anticonvulsants and antipsychotics. It would constrain state and managed care contract terms, likely making it easier for enrollees to obtain these medications without first trying other drugs or obtaining special approval, while preserving clinical safety edits and FDA-related exclusions.
Sentiment
No committee transcripts or recorded votes were provided, so there is no documented debate or vote history to indicate formal support or opposition. Based on the bill’s structure, it appears aimed at improving timely access to essential psychiatric and seizure medications, which suggests a patient-access and continuity-of-care rationale rather than a cost-containment approach.
Contention
The main policy tension is between expanding access to needed anticonvulsant and antipsychotic medications and preserving managed care tools used to control utilization and costs. Potential points of contention include whether prior authorization and step therapy are appropriate safeguards in Medicaid, the fiscal impact on the medical assistance program and managed care organizations, and whether the state will need federal approval before the change can take effect. The bill’s exceptions for clinical edits and FDA safety removals may reduce concern about patient safety, but they also show an effort to balance access with oversight.